- Home
- CELC vs HCKT Comparison
CELC vs HCKT Comparison
Compare CELC & HCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- HCKT
- Stock Information
- Founded
- CELC 2011
- HCKT 1991
- Country
- CELC United States
- HCKT United States
- Employees
- CELC N/A
- HCKT N/A
- Industry
- CELC Medical Specialities
- HCKT Professional Services
- Sector
- CELC Health Care
- HCKT Consumer Discretionary
- Exchange
- CELC Nasdaq
- HCKT Nasdaq
- Market Cap
- CELC 594.7M
- HCKT 594.0M
- IPO Year
- CELC 2017
- HCKT 1998
- Fundamental
- Price
- CELC $12.66
- HCKT $30.32
- Analyst Decision
- CELC Strong Buy
- HCKT Strong Buy
- Analyst Count
- CELC 6
- HCKT 3
- Target Price
- CELC $29.17
- HCKT $30.00
- AVG Volume (30 Days)
- CELC 257.7K
- HCKT 128.2K
- Earning Date
- CELC 11-14-2024
- HCKT 11-04-2024
- Dividend Yield
- CELC N/A
- HCKT 1.09%
- EPS Growth
- CELC N/A
- HCKT N/A
- EPS
- CELC N/A
- HCKT 1.22
- Revenue
- CELC N/A
- HCKT $300,739,000.00
- Revenue This Year
- CELC N/A
- HCKT $8.66
- Revenue Next Year
- CELC N/A
- HCKT $5.16
- P/E Ratio
- CELC N/A
- HCKT $24.85
- Revenue Growth
- CELC N/A
- HCKT 4.09
- 52 Week Low
- CELC $11.51
- HCKT $20.23
- 52 Week High
- CELC $22.19
- HCKT $32.34
- Technical
- Relative Strength Index (RSI)
- CELC 28.22
- HCKT 65.70
- Support Level
- CELC $15.33
- HCKT $24.06
- Resistance Level
- CELC $16.14
- HCKT $32.34
- Average True Range (ATR)
- CELC 0.97
- HCKT 0.92
- MACD
- CELC -0.28
- HCKT 0.45
- Stochastic Oscillator
- CELC 22.85
- HCKT 75.60
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP-based executive advisory, strategic consulting, and digital transformation firm. It provides Generative Artificial Intelligence ("Gen AI") strategy, operations, finance, human capital management, strategic sourcing, procurement, and information technology. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.